Apart from PET-based imaging, radionuclide therapy evolved as a promising treatment option for many cancer patients—with tracers for Prostate-Specific Membrane Antigen (PSMA) and Somatostatin Receptors (SSTR) being at the forefront of this development [1,2,3]. The gene discussed is FOLH1; the disease is cancer.